{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_2012_0128654_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"191-524-554-255-691","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11837,"type":"PATENT","title":"University of Cincinnati Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":2335,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8449,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: univ* AND cincinnati. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2195
Search Applicants and Owners separately: univ* AND cincinnati. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2195
a safe and effective amount of allantoin or a pharmaceutically acceptable salt, ester, racemate, or enantiomer thereof; and\n
at least one pharmaceutically acceptable excipient."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition of claim 10, wherein progression of the neurodegenerative disease is influenced by oxidative stress."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition of claim 10, wherein the neurodegenerative disease is selected from the group consisting of Parkinson's disease, Alzheimer's Disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, and Friedreich's ataxia."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition of claim 12, wherein the neurodegenerative disease is Parkinson's disease."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition of claim 10, wherein the at least one pharmaceutically acceptable excipient is selected from the group consisting of polymers, resins, plasticizers, fillers, lubricants, diluents, solvents, co-solvents, buffer systems, surfactants, preservatives, sweetening agents, flavoring agents, pharmaceutical grade dyes or pigments, viscosity agents and combinations thereof."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition of claim 10, wherein the pharmaceutical composition is an oral dosage form."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition of claim 10, further comprising a second active pharmaceutical ingredient."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition of claim 16, wherein the second active pharmaceutical ingredient is selected from the group consisting of rasagiline, levodopa, carbidopa, entacapone, ropinirole, pramipexole, donepezil, dopamine agonists, and catechol-O-methyl transferase (COMT) inhibitors."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["A method of treating damage caused by neurotrauma or cerebrovascular disease, the method comprising administering a safe and effective amount of allantoin or a pharmaceutically acceptable salt, ester, racemate, or enantiomer thereof, to a patient in need thereof."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein the damage caused by neurotrauma or cerebrovascular disease is influenced by oxidative stress."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein the cerebrovascular disease is stroke."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein administering comprises oral, intravenous, subcutaneous, and intramuscular administration."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein the administering yields a blood serum concentration of allantoin in a patient of from about 0.1 mM to about 5 mM."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, further comprising administering a second active pharmaceutical ingredient effective for the treatment of the neurodegenerative disease."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 23, wherein the second active pharmaceutical ingredient is selected from the group consisting of anti-inflammatory drugs, erythropoietin, progesterone, tissue plasminogen activator (tPA), warfarin, and aspirin."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 23, wherein the second active pharmaceutical ingredient is co-administered with allantoin."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["A pharmaceutical composition for treating damage caused by neurotrauma or cerebrovascular disease comprising:\n
a safe and effective amount of allantoin or a pharmaceutically acceptable salt, ester, racemate, or enantiomer thereof; and\n
at least one pharmaceutically acceptable excipient."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition of claim 26, wherein the damage caused by neurotrauma or cerebrovascular disease is influenced by oxidative stress."],"number":27,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition of claim 26, wherein the at least one pharmaceutically acceptable excipient is selected from the group consisting of polymers, resins, plasticizers, fillers, lubricants, diluents, solvents, co-solvents, buffer systems, surfactants, preservatives, sweetening agents, flavoring agents, pharmaceutical grade dyes or pigments, viscosity agents and combinations thereof."],"number":28,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition of claim 26, wherein the pharmaceutical composition is an oral dosage form."],"number":29,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition of claim 26, further comprising a second active pharmaceutical ingredient."],"number":30,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition of claim 30, wherein the second active pharmaceutical ingredient is selected from the group consisting of anti-inflammatory drugs, erythropoietin, progesterone, tissue plasminogen activator (tPA), warfarin, and aspirin."],"number":31,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}